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Disruption of axonal transport causes a number of rare, inherited axonopathies and is heavily 
implicated in a wide range of more common neurodegenerative disorders, many of them age-
related. Acetylation of α-tubulin is one important regulatory mechanism, influencing 
microtubule stability and motor protein attachment. Of several strategies so far used to 
enhance axonal transport, increasing microtubule acetylation through inhibition of the 
deacetylase enzyme HDAC6 has been one of the most effective. Several inhibitors have been 
developed and tested in animal and cellular models but better drug candidates are still needed. 
Here we report the development and characterisation of two highly potent HDAC6 inhibitors, 
which show low toxicity, promising pharmacokinetic properties, and enhance microtubule 
acetylation in the nanomolar range. We demonstrate their capacity to rescue axonal transport 
of mitochondria in a primary neuronal culture model of the inherited axonopathy Charcot-
Marie-Tooth Type 2F, caused by a dominantly acting mutation in heat shock protein beta 1.
Keywords: HDAC6; CMT; Axonal transport; Mitochondria, Axonopathy, α-tubulin.
INTRODUCTION
The bidirectional movement of macromolecules and organelles along axons is essential for 
axon survival and function, and requires a complex machinery involving motor proteins, 
adapters coupling to specific cargoes, microtubule tracks and regulators of all the above. Not 
surprisingly, such an essential process involving many components can malfunction in a 
number of ways and when it does the consequences can be profound. Mutation of genes 
encoding axonal transport machinery and regulators cause a number of axonopathies, and 
especially diseases of long axons. For example, mutations in KIF5A encoding a major 
anterograde motor protein are an established cause of hereditary spastic paraplegia SPG10 
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1, and have also been linked to Charcot-Marie-Tooth Disease type 2 (CMT2) 2, amyotrophic 
lateral sclerosis (ALS) 3, 4 and neonatal intractable myoclonus 5. Mutant dynactin causes motor 
neuron disease and distal spinal and bulbar muscular atrophy 6, 7 and in mice the mutation of 
tubulin chaperone protein Tbce causes a severe, early onset loss of motor axons with a major 
deficiency of microtubules 8. 
Charcot-Marie-Tooth Disease type 2 (CMT2) is an axonal, non-demyelinating peripheral 
neuropathy characterized by distal muscle weakness and atrophy, mild sensory loss, and 
normal or near-normal nerve conduction velocities 9. The Charcot-Marie-Tooth disease 
subtype 2F (CMT2F) and distal hereditary motor neuropathy subtype 2B (dHMN2B) are 
caused by autosomal dominantly inherited mutations in the small heat shock protein B1 
(HSPB1) gene 10, 11. The gene codes for heat shock protein beta-1 (HSPB1, also known as 
HSP27), which is a member of the small heat shock protein family comprising a highly 
conserved 𝛼-crystalline domain. HSPB1 acts as a chaperone binding with partially denatured 
proteins to prevent aggregation 12, 13. Up to now, 18 mutations in HSPB1 have been linked to 
CMT2F and 27 mutations to dHMN 2 14. The S135F and P182L mutations are among the best 
characterized mutations so far 11, 15, 16. The S135F mutation is the only one that causes both 
CMT2 and dHMN2B. P182L mutation is associated only with dHMN2B 15. The S135F mutation 
is located in the 𝛼-crystallin domain while P182L mutation lies in the short C-terminal tail of 
the protein 15. Interestingly the localization of the mutation was shown to have different effects 
on the protein function. While the S135F mutation caused the protein to increase its chaperone 
activity accompanied with an increased in its monomeric state the chaperone activity of 
HSPB1 was not affected by the P182L mutation 17.
Four mutant HSPB1 transgenic mouse models of CMT2F and/or dHMN2B have been 
developed so far, which partially recapitulate the hallmarks of peripheral neuropathy 11, 18-20.
S135F and P182L transgenic mice generated by d’Ydewalle et al. demonstrated noticeable 
phenotypes, the latter presents more like dHMN2B than CMT2F with a lack of sensory 
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symptoms 11 which recapitulates all key features of CMT2F or distal HMN2B, dependent on 
the mutation. However, CMT2F mouse models generated by other groups had notable 
differences. S135F transgenic mice reported by Lee et al. had no sensory phenotype and 
presented only a strict motor loss, similar to the P182L, but not the S135F mice of d’Ydewalle 
et al 18. In further contrast, the R136W mouse model did not demonstrate any functional or 
behavioral deficits 20. When R127W and P182L mutant proteins were expressed at 
physiological levels to alleviate concerns of artifacts due to overexpression, no pathology and 
behavioural deficits were found in mice 19. This could be due to insufficient expression of 
HSPB1 under the ROSA26 locus.
In addition to rare disorders and animal models, axonal transport deficiency is heavily 
implicated in many more common neurodegenerative and axonal disorders. Several cancer 
chemotherapeutics that cause peripheral neuropathy as a dose-limiting complication target 
microtubules 21 and disrupt axonal transport 22. In Alzheimer’s disease, aggregation of 
microtubule associated protein tau, whose normal functions include regulation of microtubule 
stability and motor protein attachment 23, 24 plays a prominent role, exogenously applied Aβ1-
42 is able to disrupt axonal transport in a tau-dependent manner 25. The two may also interact 
26 and impairment of axonal transport exacerbates animal models 27. There are many 
indications of a wider role also in ALS 28, Huntington’s disease 29, Parkinsonism and 
frontotemporal dementia 30, 31, and normal ageing, the biggest risk factor in each of these 32, 
is accompanied by a twofold decline in axonal transport 33. Thus, rare but often better-
understood inherited disorders involving an axonal transport mechanism are an important 
starting point to develop therapies that could have far wider application in neurodegenerative 
disease.
Axonal microtubules exist in a state of dynamic instability 34, 35, constantly both growing and 
severing to maintain them typically between 0.15-20 µm in length 36. Acetylation of α-tubulin 
at Lys40 is reported to increase microtubule stability under mechanical stress 37 and to 
influence severing by katanin 38. It also enhances the binding of kinesin-1 and axonal transport 
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39, 40. Beside SIRT2 41 HDAC6 is the other major deacetylase for α-tubulin and its inhibition 
increases axonal transport of some cargoes in models of Charcot-Marie-Tooth disease types 
2F 11 and 2D 42, ALS 43, and Vincristine neuropathy 44, also alleviating some symptoms. 
Beneficial outcomes have also been reported in models of Alzheimer’s disease 45 and stroke 
46 . Early studies of HDAC6 inhibition used tubacin, whose high lipophilicity and short in vivo 
half-life limited its usefulness. This was largely superseded by the development of Tubastatin 
A 47. However, further improvement of potency is possible 48, 49 so it is important to develop 
new compounds targeting HDAC6 with greater potential for clinical application.
The HDAC inhibitors share a well-recognized pharmacophore that consists of three parts: a 
zinc binding group (ZBG), a linker, and a cap moiety. Classical HDAC inhibitors typically have 
the hydroxamic acid moiety as ZBG but the hydroxamic acid causes poor pharmacokinetics, 
low selectivity profiles, and production of active metabolites 50. These features of hydroxamic 
acid are red flags for drug discovery in chronic diseases that are not life threatening. Therefore, 
we focussed here on the discovery of non-hydroxamic acid derivatives. High throughput 
screening (HTS) with a Takeda internal library provided several non-hydroxamic acid 
derivatives as hit compounds against HDAC6. By our medicinal chemistry efforts, we 
developed two compounds T-3796106 and T-3793168 that are highly selective for HDAC6, 
show CNS penetration and low toxicity both in vivo and in vitro. We report their dose-response 
effects for α-tubulin acetylation in primary neuronal cultures and their influence on axonal 
transport of mitochondria in a primary culture model of CMT2F.
RESULTS
Evaluation of inhibitory potencies (IC50) of T-3796106 and T-3793168
The inhibitory potencies (IC50) of T-3796106 and T-3793168, which were developed through 
medicinal chemistry campaign from HTS hit compounds, were evaluated in HDAC panel assay 
(Table 1). T-3796106 showed potent inhibitory activity against HDAC6 with the IC50 value of 
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12 nM. IC50 values for HDAC3, HDAC8, HDAC5, HDAC7, and HDAC9 were in the range of 
1,000-3,000 nM. IC50 values for HDAC1 and HDAC4 were over 6,000 nM. T-3796106 did not 
show inhibitory activity against HDAC2, HDAC10, and HDAC11 up to 10,000 nM. IC50 values 
of T-3793168 were 86 nM for HDAC6 and over 2,000 nM against other HDACs.
Target Compounds IC50 (nM)a
　 T-3796106 T-3793168 Tubastatin A
HDAC1 6200 (5820-6660) b >10000
HDAC2 >10000 b >10000
HDAC3 4000 (3480-4470) b >10000
HDAC8 >1000 5600 (4170-7080) >1000
HDAC4 6200 (5970-6380) >10000 6200 (6030-6330)
HDAC5 1700 (1610-1800) 2300 (1550-3060) 1900 (1580-2310)
HDAC7 1100 (1050-1130) 5800 (4000-7660) 590 (530-641)
HDAC9 2700 (2540-2840) 5000 (4950-4960) 1100 (913-1380)
HDAC6 12 (12.3-12.4) 86 (67.4-104) 15 (14.3-15.2)
HDAC10 >10000 b >10000
HDAC11 >10000 b >10000
Table 1 HDAC panel assay. The selectivity of T-3796106 and T-3793168 was 
analyzed based on HDAC enzyme inhibition. [a] The compound activity against 11 
HDACs represented with the IC50 value. The IC50 values shown are the mean values 
of duplicate measurements; the numbers in parentheses represent each data. [b] No 
inhibition or compound activity that could not be fit to an IC50 curve.
T-3796106 and T-3793168 do not cause neuronal toxicity even at high concentrations
First, we tested whether T-3796106 or T-3793168 induces any cytotoxicity in murine neuronal 
explant cultures, using concentrations substantially higher than those we subsequently used 
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for axonal transport studies to indicate a large therapeutic window. We used superior cervical 
ganglion (SCG) explants because this neuron type is well-suited for genetic manipulation by 
microinjection and for axonal transport studies 51, 52, and incubated with concentrations from 1 
µM to 100 µM for 24 h. No toxicity was observed at any concentration. Neurites remained 
morphologically similar to vehicle-treated or untreated cultures, even in their distal terminals 
which are typically the most vulnerable site (Fig 1A, B). Thus, both compounds are safe for 
neurons up to 100 µM for at least 24 h.
Increased acetylation levels of α-tubulin after T-3796106 and T-3793168 treatment in 
neurons
We next confirmed that steady state α-tubulin acetylation increases with either T-3796106 or 
T-3793168 within the above concentration range (data not shown), before titrating down to 
determine the dose-response curve for α-tubulin acetylation at sub-saturating levels, thereby 
minimizing the risk of off-target effects. Both compounds showed a clear dose-response effect 
between 1 nM and 250 nM in a 24 h incubation (Fig 2A), reaching significance at 50 nM for T-
3796106 and 250 nM for T-3793168 (Fig 2B). Based on this characterization we used 
concentrations of 100 nM and 250 nM respectively in our subsequent axonal transport 
experiments. At these concentrations, there was no effect on histone acetylation which 
indicates a high selectivity of these compounds towards HDAC6 (Supplementary Figure 1).
Axonal transport of mitochondria in wild type SCG cultures is not altered by T-3796106 
or T-3793168  
In the absence of a pathogenic mutation, we found no significant change in either the number 
or the average and maximum velocity of axonally transported mitochondria in dissociated wild-
type SCG neurons treated with T-3796106, T-3793168 or Tubastatin A (Fig 3B, C, D, E). Thus, 
there is no change in basal axonal transport parameters for this cargo.
Mitochondrial transport impairment induced by S135F mutation is rescued by T-
3793168
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In the presence of the HSPB1S135F mutation, which causes CMT2 and distal HMN in patients 
15, both the numbers of anterogradely and retrogradely moving mitochondria were significantly 
decreased relative to wild type neurons 12 h after microinjection (Fig 4A, B), mirroring similar 
changes reported in sensory neurons 11. The transport deficits in both directions were 
significantly rescued in neurons treated for 24 h with 250 nM T-3793168, while those treated 
with 100 nM compound T-3796106 showed a trend towards increased mitochondrial transport 
but the difference was not statistically significant (Fig 4A, B). As previously reported 11, we 
also found a rescue of anterograde axonal transport with 1 µM Tubastatin A, but in the 
retrograde direction the trend towards a rescue with Tubastatin A was not significant. The 
average and maximum speed of mitochondria movement was not significantly altered in the 
neurons with the HSPB1S135F mutation and was unaffected by any of these treatments (Fig 4C, 
D).
P182L mutation does not alter mitochondrial transport in SCG neurons
Consistent with previous findings in sensory neurons 11, SCG neurons expressing 
HSPB1P182L showed no significant changes in mitochondrial transport compared to wild type 
neurons (Fig 5). Treatment of these mutant-expressing neurons with T-3796106, T-3793168 
or Tubastatin A also had no effect on mitochondrial movement (Fig 5). 
T-3796106 and T-3793168 increase α-tubulin acetylation in human whole blood
We finally investigated the effects of T-3796106 and T-3793168 on acetylation of α-tubulin in 
human cells, using whole blood. For both compounds, clear dose-response effects were 
observed between 10 nM and 30 μM in a 4 h incubation (Fig 6). Over 100 μM of our 
compounds and 300 μM of hydroxamic acid-based HDAC6 inhibitor ACY-1215 showed 
some precipitate when the compounds were added in the culture medium. We also observed 
the effect of Tubastatin A on acetylated a-tubulin in the human whole blood assay. It showed 
a similar trend. In brief, the levels of acetylated a-tubulin were almost the same at 10 and 30 
µM of Tubastatin A (data not shown) as well as that of ACY-1215.
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We report the development and characterization of two novel non-hydroxamic acid-based 
inhibitors with high potency and specificity for HDAC6, low toxicity in murine primary 
neuronal cultures and a dose-dependent effect on neuronal α-tubulin acetylation between 1-
250 nM. T-3793168 significantly increases both the anterograde and retrograde flux of 
mitochondria in axonal transport within 24 h of application to neurons expressing the CMT-
2F HSPB1 mutation S135F, and T-3796106 shows a similar, albeit non-significant trend. 
Neither alters axonal transport in wild-type cells.
For both compounds the changes in acetylated tubulin in whole blood was several orders of 
magnitude greater than those in mouse primary neuronal cultures.  This suggests a tissue-, 
tubulin isoform-, or species-specific effect on the efficacy of these HDAC6 inhibitors 
indicating significant scope of lead compound optimization. Further studies to understand the 
basis of this specificity should help to optimize their efficacies to achieve substantial 
enhancement of axonal transport in human axonal disorders.
A major advantage over hydroxamic acid-based inhibitors is greater selectivity over other 
HDAC family members and this is the case for these compounds. For example, hydroxamic 
acid-based HDAC6 inhibitor ACY-1215 has a high HDAC6 enzyme potency with IC50 value 
of 4.7 nM but much lower selectivity (12-fold selectivity for HDAC6 and HDAC1 at IC50) 53. In 
contrast, non-hydroxamic acid-based HDAC6 inhibitors T-3796106 and T-3793168 showed 
excellent selectivity (>25-fold over other HDAC family members; >100-fold selectivity over 
HDAC1 at IC50).
It will be important now to test the effect of these compounds on axonal transport in other 
disease models where transport is impaired and the effect on other axonal transport 
cargoes. For example, axonal transport defects underlie vincristine neuropathy and some 
forms of hereditary spastic paraplegia and ALS, and have also been implicated in glaucoma, 
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Alzheimer’s disease and multiple sclerosis. Many axonal transport cargoes need to be 
continuously shuttled back and forth but among some of the most important ones are 
NMNAT2, whose absence limits the survival of transected axons 51 and the retrograde 
transport of lysosomes to maintain efficient autophagy and mitochondrial quality control 54, 
and neurotrophins. 
Finally, it will be important to test the efficacy of HDAC6 inhibition and rescue of axonal 
transport in vivo using methods for live imaging of transport cargoes in live nerves and CNS 
tissue 33, 55, 56, to assess how HDAC6 inhibition compares to other methods of boosting 
axonal transport in experimental models 57, 58 and to further develop these lead compounds.
METHODS
Chemicals
T-3796106 and T-3793168 are novel HDAC6 inhibitors developed by Takeda Pharmaceutical 
Company Limited (Patent WO2017014321)59.The purity of T-3796106 and T-3793168 was 
determined to be ≥ 95% by elemental analysis which was performed by Sumika Chemical 
Analysis Service, Ltd. experimentally determined hydrogen, carbon, and nitrogen composition 
by elemental analysis was within ±0.4% of the expected value, implying a purity of ≥ 95%. 
ACY-1215 was synthesized and determined to be ≥ 95% purity by elemental analysis by 
Takeda Pharmaceutical Company Limited.
Enzyme assay
HDAC panel assay was performed by Reaction Biology Corp. (Malvern, PA, USA) according 
to their validated protocol. To evaluate the potency and selectivity of T-3796106 and T-
3793168, HDAC panel assay was carried out by Reaction Biology Corp. Briefly, the 
deacetylation reaction was performed in buffer conditions of 50 mM Tris-HCl pH 8.0, 137 mM 
NaCl, 2.7 mM KCl, 1 mM MgCl2, and 1 mg/mL bovine serum albumin (BSA), and 1%DMSO. 
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The fluorogenic peptide, RHK-K(Ac)-AMC, is used as substrate for Class1 and 2B HDACs, 
RHK(Ac)K(Ac)-AMC for HDAC8, and Boc-Lys(trifluoroacetyl)-AMC for Class2A HDACs. After 
the reaction, by Developer with Trichostatin A, a fluorescence signal (Ex. 360 nm/Em. 460 
nm) developed.
Animals
C57BL/6JOlaHsd mice were obtained from Harlan UK (Bicester, UK). All animal work was 




SCGs were dissected from 0 to 2 days old C57BL/6 (wild-type) mouse pups. Cleaned explants 
were placed in the centre of 3.5 cm tissue culture dishes pre-coated with poly-L-lysine (20 
mg/mL for 1–2 h; Sigma) and laminin (20 mg/mL for 1–2 h; Sigma). Explants were cultured in 
Dulbecco’s Modified Eagle’s Medium (DMEM) with 4,500 mg/L glucose and 110 mg/L sodium 
pyruvate (Sigma), 2 mM glutamine (Invitrogen), 1% penicillin/streptomycin (Invitrogen), 100 
ng/mL 7S NGF (Invitrogen), and 10% fetal bovine serum (Sigma). Four µM aphidicolin 
(Calbiochem) was used to reduce proliferation and viability of small numbers of non-neuronal 
cells. Cultures were used after 6 days.
Dissociated SCG cultures
SCG ganglia were dissociated by incubation in 0.025% trypsin (Sigma) in PBS (without CaCl2 
and MgCl2) for 30 min followed by 0.2% collagenase type II (Gibco) in PBS for a further 20 
min. Ganglia were then gently triturated using a pipette. After a 2 h pre-plating stage to remove 
non-neuronal cells, 5,000–10,000 dissociated neurons were plated in a 1 cm2 poly-L-lysine 
and laminin-coated area in the centre of 3.5 cm ibidi μ-dishes (Thistle Scientific, Glasgow, UK) 
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for microinjection experiments or in the centre of 3.5 cm tissue culture dishes for analysis by 
western blotting. Dissociated cultures were maintained the same as explant cultures.
HDAC6 inhibitors treatment
The SCG explants and dissociated cultures were treated for 24 h at 37ºC with compound 
dosages ranging from 1 µM to 100 µM for toxicity experiments and 1nM to 250 nM for testing 
the dose-response study of α-tubulin acetylation. For axonal transport rescue experiments, 
dissociated SCG cultures were treated with either 100 nM T-3796106, 250 nM T-3793168, 1 
μM Tubastatin A or an equivalent amount of DMSO. 
Plasmid constructs
The S135F and P182L mutations were introduced separately by QuikChange II site-directed 
mutagenesis (Stratagene) into the complete open reading frame of human HSPB1 isoform 
cloned into expression vector pCMV-Tag2 (Stratagene). The mito-EGFP construct was kindly 
provided by Dr Andrea Loreto.
Microinjection
Microinjection was performed using a Zeiss Axiovert 200 microscope with an Eppendorf 5171 
transjector and 5246 micromanipulator system and Eppendorf Femtotips. Microinjection mixes 
of plasmid DNA were prepared in 0.5× PBS(−), passed through a Spin-X filter (Costar, 
Glasgow, UK) Eppendorf and injected directly into the nuclei of SCG neurons in dissociated 
cultures. Femtotips were loaded with the microinjection mix and injection was performed using 
an Eppendorf 5171 transjector and 5246 micromanipulator system on a Zeiss Axiovert 200 
microscope. All injections were carried out directly into the nuclei of dissociated SCG neurons. 
A maximum total DNA concentration of 0.05 μg/μL in the injection mix was used. Forty cells 
were injected per dish and imaging was performed 12 hours after microinjection. 
Western Blotting
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Following treatment, ganglia and neurites were collected and washed in PBS with complete, 
ethylenediaminetetraacetic acid (EDTA)-free protease inhibitor cocktail tablets (Sigma-
Aldrich), and lysed directly into 2x Laemmli sample buffer. A total of 10 μL of each sample 
were separated on a 12% SDS-PAGE and transferred to PVDF membrane (Millipore) using 
the Bio-Rad Mini-PROTEAN III wet transfer system. Blots were blocked and incubated with 
primary antibodies overnight (in 1xTBS pH. 8.3, with 0.05% Tween 20 and 5% milk powder or 
5% BSA). The antibodies were directed against α-tubulin (1/5,000; ab 15246, Abcam) and 
acetylated α-tubulin (1/5,000; T7451, Sigma) and detected with mouse-700 (Life 
Technologies) and rabbit-800 (LI-COR) secondary antibodies. Blots were then scanned and 
quantified using the Odyssey imaging system (LI-COR Biosciences, Lincoln, North Carolina).
Live imaging of mitochondrial transport and image analysis
Mitochondria were labelled by microinjection of mito-EGFP and their movement along the 
neurites was recorded with an inverted spinning-disk confocal microscope Olympus IX70 
using a 100x 1.49 NA oil immersion objective (Olympus), and controlled with MetaMorph 7.7 
software (Molecular Devices). The environment was controlled with a stage top incubator 
(model INUBG2E-ZILCS; Tokai Hit), set at 37°C and CO2 set to 5%. Time lapse images of 
mitochondrial movements were acquired every 1 s for 2 min (120 frames in total). A total of 
4-5 movies from different neurons were captured from each culture dish. Individual neurites 
were straightened using the Straighten plugin in ImageJ software version 1.44 (Rasband, 
W.S., ImageJ, U. S. National Institutes of Health, Bethesda, MD; http://imagej.nih.gov/ij/, 
1997e2012). Transport parameters were determined for individual neurites using the 
Difference Tracker set of ImageJ plugins 060. The principal output of these plugins is the 
number of moving particles identified in each frame of the image, normalized to 1000 pixels 
(Figure 3A).
Human whole blood assay
Study design
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In human whole blood assay, whole human blood was collected from healthy volunteers after 
informed consent at Takeda Pharmaceutical Company Limited. 25 μL of the collected human 
whole blood was put into each well of a 96-well round-bottom plate. The whole blood was 
treated with 10 μL of diluted compounds in 10% FBS containing RPMI 1640 medium (Gibco). 
In the control group, 0.1% DMSO was added as a final concentration. After that, the treated 
whole blood was incubated at 37°C for 30 minutes at 5% CO2. Next, 65 μL of RPMI 1640 
medium was added onto each well, and the samples were incubated at 37°C for 3.5 hours. T-
3796106, T-3793168, and ACY-1215 were dissolved in 100% DMSO (to a stock concentration 
of 10-300 mM for our in vitro studies).
Measurements
For flow cytometry analyses, the compound-treated whole blood samples were transferred to 
an assay block (Costar). Diluted Lyse/Fix buffer (BD Biosciences) in dH2O was added to each 
sample with pipetting well. The samples were put at RT for 10 minutes and then centrifuged 
at 400xg for 5 minutes. After centrifugation, the supernatant was removed by aspiration. 250 
μL of Perm/Wash buffer I (BD Biosciences) was added to each well and the samples were 
transferred into a 96-well V-bottom plate, and they were incubated on ice for 20 minutes. 
These samples were centrifuged at 400xg for 5 minutes at RT, and the supernatant was 
removed by aspiration. The cells were stained with Zenon conjugated AF647 acetylated α-
tubulin (ab179484, Abcam) or matched isotype control (ab172730, Abcam) for 20-30 minutes 
on ice. Zenon Rabbit IgG Labeling Kit, AF647 (Molecular Probes) was used according to the 
provided protocol. The cells were centrifuged at 400xg at 5 minutes, and the supernatant was 
removed, and then washed with 200 μL of Perm/Wash buffer I. After re-centrifugation and 
removal of the supernatant, the samples were suspended with 200 μL of FACS stain buffer 
(1% FBS/PBS). The samples were analyzed using lymphocyte gate by BD Fortessa, and the 
results were analyzed with FlowJo software. Therefore, only lymphocytes were analyzed 
neither erythrocytes nor thrombocytes were included in the assay.
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Statistical tests, as described in the figure legends, were performed using Prism software 
(GraphPad Software Inc, La Jolla, CA, USA). A p value of >0.05 was considered not significant 
(ns) and *p < 0.05 was significant.
SUPPORTING INFORMATION
Supplementary method and extended western blot results.
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Figure 1. Morphologically normal neurites of SCG explants treated with high concentrations of T-3796106 
and T-3793168. (A) Vehicle treated and untreated cultures have healthy looking neurites with no signs of 
fragmentation or blebbing. (B) Cultures treated with indicated compound concentrations look 
morphologically similar with control cultures, which suggest no cytotoxic effect. Scale bar 50 µm. 
168x117mm (300 x 300 DPI) 
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Figure 2. Pharmacological properties of T-3796106 and T-3793168 in SCG neurons. Western blot showing 
dose response of T-3796106 and T-3793168 (A) on acetylation of α-tubulin. 1 µM Tubastatin A (Tub) was 
used as positive control. Quantification of the ratio of acetylated α-tubulin to total tubulin levels on Western 
blot for T-3796106 and T-3793168 (B). Statistically significant difference between groups is indicated (*p < 
0.05, 1-way analysis of variance). Data are presented as means ± s.e.m. n=4-5. 
168x117mm (300 x 300 DPI) 
Page 25 of 29































































Figure 3. Mitochondrial transport remains unaltered in wild type SCGs after treatment.  Representative 
kymograph obtained from a SCG neuron grown in dissociated cultures (A). The top image shows a 
straightened neurite. Vertical lines indicate stationary mitochondria while lines deflecting to the right or left 
represent anterograde or retrograde moving mitochondria. Time (t) scale bar: 120 s; distance (d) scale bar: 
10 μm. Quantification of anterograde (B) and retrograde (C) mitochondria transport, average (D) and 
maximum speed (E) of mitochondria movement in neurons treated with the indicated compounds and 
concentrations. Data are presented as means ± s.e.m. n=12-14. 
168x117mm (300 x 300 DPI) 
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Figure 4. T-3793168 reverses axonal transport deficit in SCGs with HSPB1S135F mutation. Quantification of 
anterograde (A) and retrograde (B) mitochondria transport, average (C) and maximum speed (D) of 
movement with genotypes and treatments indicated. Statistically significant differences between groups is 
indicated (*p < 0.05, 1-way analysis of variance). Data are presented as means ± s.e.m. n=12-17. 
168x117mm (300 x 300 DPI) 
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Figure 5. No changes in axonal transport of SCGs with HSPB1P182L mutation. Quantification of anterograde 
(A), retrograde (B), average (C) and maximum speed (D) of mitochondria transport with genotypes and 
treatments indicated. Data are presented as means ± s.e.m. n=12-14. 
168x117mm (300 x 300 DPI) 
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Figure 6. Increased acetylation levels of α-tubulin in human whole blood. Quantification of acetylated α-
tubulin in whole blood treated with the indicated compounds and concentrations. Data are presented as 
means ± s.e.m. n=3. 
168x117mm (300 x 300 DPI) 
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